SGLT-2 inhibitors for COVID-19 — A miracle waiting to happen or just another beat around the bush?
- 1 October 2020
- journal article
- letter
- Published by Elsevier in Primary Care Diabetes
- Vol. 14 (5) , 564-565
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesisDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- Endocrine and metabolic link to coronavirus infectionNature Reviews Endocrinology, 2020
- Laboratory Parameters in Detection of COVID-19 Patients with Positive RT-PCR; a Diagnostic Accuracy Study2020
- Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysisJournal of Thrombosis and Thrombolysis, 2019
- SGLT-2 Inhibitors and Peripheral Artery Disease: A Statistical Hoax or Reality?Current Problems in Cardiology, 2019
- Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular diseaseDiabetes & Metabolism, 2018
- Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal OutcomesCurrent Diabetes Reviews, 2018
- Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilationDiabetologia, 2017
- SGLT2 Inhibitors as a Therapeutic Option for Diabetic NephropathyInternational Journal of Molecular Sciences, 2017
- Na + /H + Exchanger Inhibitor, SM-20220, Is Protective Against Excitotoxicity in Cultured Cortical NeuronsStroke, 2004